Molecular Diagnostics Global Market- Forecast to 2026

Publishing Date : February, 2020
Report Code : HCMD0165
Price:
Single license $4,950
Site license $6,750
Global license $9,000


There is an emerging trend towards precision health in today’s world to enhance disease diagnosis, treatment, prevention and monitoring by using innovative diagnostic technologies with broader range and bioinformatics. Molecular diagnostics is a set of techniques used for detection and monitoring of genetic variants such as DNA, RNA and proteins associated with a disease. Molecular diagnostic tests are the key drivers for the better management and treatment of diseases thereby providing critical information to patients for right medical decisions. By providing rapid and precise information about the disease, molecular diagnostics have revolutionized the healthcare system across the world.

Some of the advantages of molecular diagnostics are, up to 70% of the healthcare decisions are influenced by molecular based tests, improve the quality of personalized care of the patient, potential improvement in the patient outcome and facilitate early detection of diseases with sensitive assays thereby reducing the cost of healthcare of an individual.

According to IQ4I analysis, molecular diagnostics global market is estimated to reach $18,668.9 million by 2026 growing at a high single digit CAGR from 2019 to 2026. Among the overall molecular diagnostic market is increasing prevalence of different types of cancers, infectious diseases, genetic disorders and other diseases, increasing awareness in personalized medicine and companion diagnostics and also growth in the point of care testing and sequencing-based tests and other molecular techniques. Molecular diagnostics plays a pivotal role in the evaluation of the disease and for the effective response for specific therapy. However, the complex regulations for the approval of molecular diagnostic tests, availability of competing/alternative technologies, high cost of the tests, and also shortage of technical experts are some of the restrains for the growth of the molecular diagnostics market.

The molecular diagnostics global market is segmented based on product, technology, application and end-users. The product market is further categorized into instruments, consumables and software and services. As per IQ4I research estimations, the consumable global market commanded the largest revenue in 2019 and is projected to grow at double digit CAGR from 2019 to 2026.

The molecular diagnostics global market by technology is divided into PCR, microarray and microfluidics, isothermal nucleic acid amplification tests, in-situ hybridization, NGS and other technologies. PCR accounted for the largest revenue in 2019 and is expected to grow at a double digit CAGR from 2019 to 2026 due to low cost and is a common and indispensable technique used for diagnosis when compared to other instruments such as NGS and also due to technological advancements in PCR and their subtypes such as digital droplet PCR with precise and highly sensible results.

The molecular diagnostics by application is classified into infectious diseases, oncology, genetic testing, transplantation, blood screening and other diseases such as metabolic disorders and diseases associated with central nervous system. The largest revenue was contributed by infectious diseases segment in 2019 and this market is expected to grow at a high single digit CAGR from 2019 to 2026 due to high incidence of bacterial and viral infections.

Infectious diseases are further segmented into bacterial, viral and other diseases. The viral diseases commanded the largest revenue in 2019 and the market is expected to grow at a strong double digit CAGR from 2019 to 2026. Viral diseases are further segmented into HIV, hepatitis, HPV, influenza and other viral infections. Among theses, HIV accounted for the largest revenue in 2019 and is expected grow at a double digit CAGR from 2019 to 2026. The bacterial diseases are sub-segmented into sexually transmitted diseases (STD) caused by bacteria, hospital acquired infections, tuberculosis and other diseases such as sepsis, pneumonia and meningitis etc. Sexually transmitted disease accounted for the largest revenue in 2019 and is expected to grow at high single digit CAGR from 2019 to 2026. The growth is attributed to the increase awareness about the molecular based kits available for the diagnoses of STD’s and also increase in the prevalence.

Under genetic testing segment the market is segmented into NIPT, cystic fibrosis and other genetic testing, among them NIPT commanded the largest revenue in 2019 and is expected to grow at a double digit CAGR from 2019 to 2026 as NIPT provides a safer alternative to invasive tests and it analyzes fetal cell-free DNA (cfDNA) from the mother’s circulation, making early detection of genetic disorders such as Down syndrome and other chromosomal aberrations easier.

Based on type of cancer, the oncology market is segmented into lung, breast, colorectal, prostate, ovarian, melanoma, ovarian and other cancers. The largest revenue under oncology was accounted by colorectal cancer with the revenue in 2019 and breast cancer is expected to grow at double digit CAGR from 2019 to 2026. Based on the cancer care, oncology segment is sub divided into early screening, companion diagnostics, prognosis and recurrence. Early screening contributed for largest revenue in 2019 and companion diagnostics is expected to grow at double digit CAGR from 2019 to 2026. Further, transplantation market is segmented into kidney, heart and other transplantation such as lung and pancreatic transplantation. Among them, kidney transplantation commanded the largest revenue in 2019.

Molecular diagnostics, end users market is segmented into hospitals, clinical/centralized laboratories, academics and research and other end users. Clinical/centralized laboratories accounted for the largest revenue due to the rapid adoption of technology and economies of scale in testing large number of samples collected from affiliated hospitals.

Geographical wise, North America region commanded the largest revenue in 2019 and is expected grow at a mid single digit CAGR from 2019 to 2026 owing to the high demand for early detection, treatment selection and prevention of diseases with advanced technology due to diseases associated with the lifestyle. However, Asia-pacific region is expected to grow at a early teen CAGR from 2019 to 2026 attributing to increasing awareness of the molecular based test for the better outcome. 

The molecular diagnostics global market is a competitive market and all the existing players in this market are involved in developing new and advanced molecular based techniques for diagnosis to maintain their market shares and also acquiring companies for product expansion.

Some of the key players in molecular diagnostics global market are Abbott Laboratories (U.S.), F.Hoffmann-LA Roche AG (Switzerland), BioMerieux (France), Qiagen (Netherlands) Exact Sciences (U.S.), Grifols (Spain), Danaher Corporation (U.S.), Hologic, Inc. (U.S.), and Myriad Genetics, Inc. (U.S.)

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

•           North America (U.S. and Rest of N.A.)

•           Europe (Germany, France, Italy and Rest of E.U.)

•           Asia-Pacific (Japan, China, India and Rest of APAC)

•           Rest of the World (RoW) (Brazil, Rest of Latin-America and Middle East & Others)

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITY
        • 3.3.1.1     INCREASING INCIDENCE OF INFECTIOUS DISEASES
        • 3.3.1.2     RISING INCIDENCE OF CANCER AND NON-INFECTIOUS DIEASES
        • 3.3.1.3     TECHNOLOGICAL ADVANCEMENTS
        • 3.3.1.4     FAVORABLE REIMBURSEMENTS
        • 3.3.1.5     INVESTMENT BY MAJOR PLAYERS
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     LACK OF SKILLED PROFESSIONALS
        • 3.3.2.2     HIGH COST OF MOLECULAR DIAGNOSTICS PRODUCTS
        • 3.3.2.3     LACK OF STANDARDIZATION OF THE MOLECULAR DIAGNOSTICS TEST
        • 3.3.2.4     STRINGENT AND TIME-CONSUMING REGULATORY ISSUES
        • 3.3.2.5     LACK OF REPRODUCIBILITY AND REPEATABILITY
        • 3.3.2.6     BIOCHEMICAL AND ALTERNATIVE TESTS
    • 3.4     MARKET SHARE ANALYSIS
      • 3.4.1     MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
      • 3.4.2     MOLECULAR DIAGNOSTICS IN INFECTIOUS DISEASES MARKET SHARE
    • 3.5     REGULATORY AFFAIRS
      • 3.5.1     U.S.
      • 3.5.2     EUROPE
      • 3.5.3     CHINA
      • 3.5.4     INDIA
      • 3.5.5     JAPAN
      • 3.5.6     AUSTRALIA
      • 3.5.7     SOUTH KOREA
    • 3.6     REIMBURSEMENT SCENARIO
    • 3.7     CLINICAL TRIALS
      • 3.7.1     CTDNA CLINICALTRIALS
      • 3.7.2     CFDNA CLINICALTRIALS
      • 3.7.3     CIRCULATING TUMOR CELLS
      • 3.7.4     COMPANION DIAGNOSTICS
    • 3.8     LATEST AND UPCOMING PRODUCTS
    • 3.9     PORTER’S FIVE FORCE ANALYSIS
      • 3.9.1     THREAT OF NEW ENTRANTS
      • 3.9.2     THREAT OF SUBSTITUTES
      • 3.9.3     COMPETITIVE RIVALRY
      • 3.9.4     BARGAINING POWER OF SUPPLIERS
      • 3.9.5     BARGAINING POWER OF BUYERS
    • 3.10     FUNDING SCENARIO
  • 4     MARKET SIZING
    • 4.1     U.S.CANCER CARE MARKET SIZING INFORMATION
      • 4.1.1     ONCOLOGY TESTING
        • 4.1.1.1     EARLY SCREENING
        • 4.1.1.2     COMPANION DIAGNOSTICS
        • 4.1.1.3     PROGNOSIS MONITORING
        • 4.1.1.4     RECURRENCE MONITORING
      • 4.1.2     NON-INVASIVE PRENATAL SCREENING (NIPT)
      • 4.1.3     TRANSPLANTATION DIAGNOSTICS
  • 5     MOLECULAR DIAGNOSTICS GLOBAL MARKET, BY PRODUCTS
    • 5.1     INTRODUCTION
    • 5.2     INSTRUMENTS
    • 5.3     CONSUMABLES
    • 5.4     SOFTWARE AND SERVICES
  • 6     MOLECULAR DIANOSTICS GLOBAL MARKET BY TECHNOLOGY
    • 6.1     INTRODUCTION
    • 6.2     PCR
    • 6.3     MICROFLUIDICS AND MICROARRAY
    • 6.4     ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
    • 6.5     IN-SITU HYBRIDIZATION
    • 6.6     NEXT GENERATION SEQUENCING (NGS)
    • 6.7     OTHERS
  • 7     MOLECULAR DIAGNOSTICS GLOBAL MARKET, BY APPLICATION
    • 7.1     INTRODUCTION
    • 7.2     INFECTIOUS DISEASES
      • 7.2.1     BACTERIAL DISEASES
        • 7.2.1.1     SEXUALLY TRANSMITTED DISEASES
        • 7.2.1.2     HOSPITAL ACQUIRED INFECTIONS
        • 7.2.1.3     TUBERCULOSIS
        • 7.2.1.4     OTHERS
      • 7.2.2     VIRAL DISEASES
        • 7.2.2.1     HIV
        • 7.2.2.2     HEPATITIS
        • 7.2.2.3     INFLUENZA
        • 7.2.2.4     HUMAN PAPILOMA VIRUS (HPV)
        • 7.2.2.5     OTHER VIRAL DISEASES
      • 7.2.3     OTHER INFECTIOUS DISEASES
    • 7.3     GENETIC TESTING
      • 7.3.1     NON-INVASIVE PRENATAL TESTING (NIPT)
      • 7.3.2     CYSTIC FIBROSIS
      • 7.3.3     OTHER GENETIC DISEASES
    • 7.4     ONCOLOGY TESTING
      • 7.4.1     CANCER TYPES
        • 7.4.1.1     INTRODUCTION
        • 7.4.1.2     LUNG CANCER
        • 7.4.1.3     BREAST CANCER
        • 7.4.1.4     COLORECTAL CANCER
        • 7.4.1.5     PROSTATE CANCER
        • 7.4.1.6     MELANOMA
        • 7.4.1.7     OVARIAN CANCER
        • 7.4.1.8     OTHERS
      • 7.4.2     CANCER CARE
        • 7.4.2.1     INTRODUCTION
        • 7.4.2.2     EARLY SCREENING
        • 7.4.2.3     COMPANION DIAGNOSTICS
        • 7.4.2.4     PROGNOSIS MONITORING
        • 7.4.2.5     RECURRENCE MONITORING
    • 7.5     TRANSPLANTATION
      • 7.5.1     KIDNEY TRANSPLANTATION
      • 7.5.2     HEART TRANSPLANTATION
      • 7.5.3     OTHER TRANSPLANTATION
    • 7.6     BLOOD SCREENING
    • 7.7     OTHER DISEASES
  • 8     MOLECULAR DIAGNOSTICS GLOBAL MARKET, BY END USERS
    • 8.1     INTRODUCTION
    • 8.2     HOSPITALS
    • 8.3     CLINICAL/CENTRALIZED LABORATORIES
    • 8.4     ACADEMIC AND RESEARCH
    • 8.5     OTHERS
  • 9     MOLECULAR DIAGNOSTICS GLOBAL MARKET, BY REGION
    • 9.1     INTRODUCTION
    • 9.2     NORTH AMERICA
      • 9.2.1     U.S.
      • 9.2.2     REST OF NORTH AMERICA
    • 9.3     EUROPE
      • 9.3.1     FRANCE
      • 9.3.2     GERMANY
      • 9.3.3     ITALY
      • 9.3.4     REST OF EUROPE
    • 9.4     ASIA-PACIFIC REGION
      • 9.4.1     CHINA
      • 9.4.2     INDIA
      • 9.4.3     JAPAN
      • 9.4.4     REST OF ASIA-PACIFIC
    • 9.5     REST OF THE WORLD
      • 9.5.1     BRAZIL
      • 9.5.2     REST OF LATIN AMERICA
      • 9.5.3     MIDDLE EAST AND OTHERS
  • 10     COMPETITIVE LANDSCAPE
    • 10.1     INTRODUCTION
    • 10.2     APPROVALS
    • 10.3     COLLABORATIONS
    • 10.4     ACQUISITIONS
    • 10.5     NEW PRODUCT LAUNCHES
    • 10.6     OTHERS
  • 11     MAJOR COMPANIES
    • 11.1     ABBOTT LABORATORIES
      • 11.1.1     OVERVIEW
      • 11.1.2     FINANCIALS
      • 11.1.3     PRODUCT PORTFOLIO
      • 11.1.4     KEY DEVELOPMENTS
      • 11.1.5     BUSINESS STRATEGY
      • 11.1.6     SWOT ANALYSIS
    • 11.2     BECTON, DICKINSON AND COMPANY
      • 11.2.1     OVERVIEW
      • 11.2.2     FINANCIALS
      • 11.2.3     PRODUCT PORTFOLIO
      • 11.2.4     KEY DEVELOPMENTS
      • 11.2.5     BUSINESS STRATEGY
      • 11.2.6     SWOT ANALYSIS
    • 11.3     BIOMÉRIEUX
      • 11.3.1     OVERVIEW
      • 11.3.2     FINANCIALS
      • 11.3.3     PRODUCT PORTFOLIO
      • 11.3.4     KEY DEVELOPMENTS
      • 11.3.5     BUSINESS STRATEGY
      • 11.3.6     SWOT ANALYSIS
    • 11.4     DANAHER CORPORATION
      • 11.4.1     OVERVIEW
      • 11.4.2     FINANCIALS
      • 11.4.3     PRODUCT PORTFOLIO
      • 11.4.4     KEY DEVELOPMENTS
      • 11.4.5     BUSINESS STRATEGY
      • 11.4.6     SWOT ANALYSIS
    • 11.5     EXACT SCIENCES CORPORATION
      • 11.5.1     OVERVIEW
      • 11.5.2     FINANCIALS
      • 11.5.3     PRODUCT PORTFOLIO
      • 11.5.4     KEY DEVELOPMENTS
      • 11.5.5     BUSINESS STRATEGY
      • 11.5.6     SWOT ANALYSIS
    • 11.6     GRIFOLS, S.A.
      • 11.6.1     OVERVIEW
      • 11.6.2     FINANCIALS
      • 11.6.3     PRODUCT PORTFOLIO
      • 11.6.4     KEY DEVELOPMENTS
      • 11.6.5     BUSINESS STRATEGY
      • 11.6.6     SWOT ANALYSIS
    • 11.7     HOLOGIC, INC.
      • 11.7.1     OVERVIEW
      • 11.7.2     FINANCIALS
      • 11.7.3     PRODUCT PORTFOLIO
      • 11.7.4     KEY DEVELOPMENTS
      • 11.7.5     BUSINESS STRATEGY
      • 11.7.6     SWOT ANALYSIS
    • 11.8     MYRIAD GENETICS, INC.
      • 11.8.1     OVERVIEW
      • 11.8.2     FINANCIALS
      • 11.8.3     PRODUCT PORTFOLIO
      • 11.8.4     KEY DEVELOPMENTS
      • 11.8.5     BUSINESS STRATEGY
      • 11.8.6     SWOT ANALYSIS
    • 11.9     QIAGEN N.V.
      • 11.9.1     OVERVIEW
      • 11.9.2     FINANCIALS
      • 11.9.3     PRODUCT PORTFOLIO
      • 11.9.4     KEY DEVELOPMENTS
      • 11.9.5     BUSINESS STRATEGY
      • 11.9.6     SWOT ANALYSIS
    • 11.10     F. HOFFMANN-LA ROCHE LTD.
      • 11.10.1     OVERVIEW
      • 11.10.2     FINANCIALS
      • 11.10.3     PRODUCT PORTFOLIO
      • 11.10.4     KEY DEVELOPMENTS
      • 11.10.5     BUSINESS STRATEGY
      • 11.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     MOLECULAR DIANGOSTICS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 2     ONCOLOGY TESTING U.S. MARKET
      • TABLE 3     NIPT GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (HIGH RISK PREGNANCIES) (2019)($MN)
      • TABLE 4     KIDNEY TRANSPLANTATION DIAGNOSTICS GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (2019)($MN)
      • TABLE 5     HEART TRANSPLANTATION DIAGNOSTIS GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (2019)($MN)
      • TABLE 6     MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 7     MOLECULAR DIAGNOSTICS INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 8     MOLECULAR DIAGNOSTICS CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 9     MOLECULAR DIAGNOSTICS SOFTWARE AND SERVICES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 10     MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 11     PCR GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 12     MICROFLUIDS AND MICROARRAY GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 13     ISOTHERMAL NUCLIEC ACID AMPLIFICATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 14     IN-SITU HYBRIDIZATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 15     NGS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 16     OTHERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 17     MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
      • TABLE 18     INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 19     INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY ORGANSIM (2018-2026) ($MN)
      • TABLE 20     BACTERIAL DISEASES GLOBAL MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
      • TABLE 21     BACTERIAL INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 22     SEXUALLY TRANSMITTED DISEASES (STD’S) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 23     HOSPITAL ACQUIRED INFECTION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 24     TUBERCULOSIS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 25     OTHER BACTERIAL DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 26     VIRAL DISEASES GLOBAL MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
      • TABLE 27     VIRAL DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 28     HIV GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 29     HEPATITIS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 30     INFLUENZA GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 31     HPV GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 32     OTHER VIRAL DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 33     OTHER INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 34     GENETIC TESTING GLOBAL MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
      • TABLE 35     GENETIC TESTING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 36     NIPT GLOBAL MARKET REVENUE, BY REGION (2018-2026)($MN)
      • TABLE 37     CYSTIC FIBROSIS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 38     OTHER GENETIC DISEASES GLOBAL MARKET REVENUE, BY PREGION (2018-2026) ($MN)
      • TABLE 39     ONCOLOGY TESTING GLOBAL MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
      • TABLE 40     CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 41     LUNG CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 42     BREAST CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 43     COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 44     PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 45     MELANOMA GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 46     OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 47     OTHER CANCERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 48     ONCOLOGY GLOBAL MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
      • TABLE 49     EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 50     COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 51     PROGNOSIS MONITORING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 52     RECURRENCE MONITORING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 53     TRANSPLANTATION GLOBAL MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
      • TABLE 54     TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 55     KIDNEY TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 56     HEART TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 57     OTHER TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 58     BLOOD SCREENING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 59     OTHER DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 60     MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USERS (2018-2026) ($MN)
      • TABLE 61     HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 62     CLINICAL/CENTRALIZED LABORATORIES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 63     ACADEMICS AND RSEARCH GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 64     OTHER END USERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 65     MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • TABLE 66     NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 67     NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 68     NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
      • TABLE 69     NORTH AMERICA INFECTIOUS DISEASES MARKET REVENUE, BY ORGANISM (2018-2026) ($MN)
      • TABLE 70     NORTH AMERICA BACTERIAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
      • TABLE 71     NORTH AMERICA VIRAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026)($MN)
      • TABLE 72     NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
      • TABLE 73     NORTH AMERICA ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
      • TABLE 74     NORTH AMERICA ONCOLOGY MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
      • TABLE 75     NORTH AMERICA TRANSPLANTATION MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
      • TABLE 76     NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2018-2026) ($MN)
      • TABLE 77     NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
      • TABLE 78     EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 79     EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 80     EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
      • TABLE 81     EUROPE INFECTIOUS DISEASES MARKET REVENUE, BY ORGANISM (2018-2026) ($MN)
      • TABLE 82     EUROPE BACTERIAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
      • TABLE 83     EUROPE VIRAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
      • TABLE 84     EUROPE GENETIC TESTING MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
      • TABLE 85     EUROPE ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
      • TABLE 86     EUROPE ONCOLOGY MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
      • TABLE 87     EUROPE TRANSPLANTATION MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
      • TABLE 88     EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2018-2026) ($MN)
      • TABLE 89     EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
      • TABLE 90     ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 91     ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 92     ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
      • TABLE 93     ASIA-PACIFIC INFECTIOUS DISEASES MARKET REVENUE, BY ORGANISM (2018-2026) ($MN)
      • TABLE 94     ASIA-PACIFIC BACTERIAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
      • TABLE 95     ASIA-PACIFIC VIRAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
      • TABLE 96     ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
      • TABLE 97     ASIA-PACIFIC ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
      • TABLE 98     ASIA-PACIFIC ONCOLOGY MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
      • TABLE 99     ASIA-PACIFIC TRANSPLANTATION MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
      • TABLE 100     ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2018-2026) ($MN)
      • TABLE 101     ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
      • TABLE 102     REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 103     REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
      • TABLE 104     REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
      • TABLE 105     REST OF THE WORLD INFECTIOUS DISEASES MARKET REVENUE, BY ORGANISM (2018-2026) ($MN)
      • TABLE 106     REST OF THE WORLD BACTERIAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
      • TABLE 107     REST OF THE WORLD VIRAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
      • TABLE 108     REST OF THE WORLD GENETIC TESTING MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
      • TABLE 109     REST OF THE WORLD ONCOLOGY TESTING MARKET REVENUE, BY TYPE OF CANCER (2018-2026) ($MN)
      • TABLE 110     REST OF THE WORLD ONCOLOGY MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
      • TABLE 111     REST OF THE WORLD TRANSPLANTATION MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
      • TABLE 112     REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2018-2026) ($MN)
      • TABLE 113     ROW MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
      • TABLE 114     APPROVALS (2018-2019)
      • TABLE 115     COLLABORATIONS/PARTNERSHIPS(2016-2018)
      • TABLE 116     ACQUISITIONS (2018-2019)
      • TABLE 117     NEW PRODUCT LAUNCH (2018-2019)
      • TABLE 118     OTHERS (2018-2019)
      • TABLE 119     ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 120     ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q3) ($MN)
      • TABLE 121     ABBOTT LABORATORIES: TOTAL REVENUE, BY DIAGNOSTIC SEGMENTS, (2017-2019) (Q3) ($MN)
      • TABLE 122     ABBOTT LABORATORIES:TOTAL REVENUE, BY REVENUE IN REGIONS, (2017-2019) (Q3) ($MN)
      • TABLE 123     BECTON, DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES (2017-2019)(Q3) ($MN)
      • TABLE 124     BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENT, (2017-2019)(Q3) ($MN)
      • TABLE 125     BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY REGION, (2017-2019(Q3)) ($MN)
      • TABLE 126     BIOMÉRIEUX: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 127     BIOMÉRIEUX: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
      • TABLE 128     BIOMÉRIEUX: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
      • TABLE 129     DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 130     DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
      • TABLE 131     DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
      • TABLE 132     EXACT SCIENCES CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 133     EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY REVENUE SOURCES (2017-2019) ($MN)
      • TABLE 134     GRIFOLS, S.A.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 135     GRIFOLS, S.A.: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
      • TABLE 136     GRIFOLS, S.A.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
      • TABLE 137     HOLOGIC, INC. : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 138     HOLOGIC, INC.: TOTAL REVENUE, BY REVENUE SEGMENT, (2017-2019) (Q3) ($MN)
      • TABLE 139     HOLOGIC, INC.: TOTAL REVENUE, BY PRODUCT, (2017-2019)(Q3) ($MN)
      • TABLE 140     HOLOGIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
      • TABLE 141     MYRIAD GENETICS, INC : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 142     MYRIAD GENETICS: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 143     MYRIAD GENETICS:DIAGNOSTICS AND OTHERS BY PRODUCT SEGMENT, (2017-2019) ($MN)
      • TABLE 144     QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 145     QIAGEN N.V.: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
      • TABLE 146     QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
      • TABLE 147     F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 148     F. HOFFMANN-LA ROCHE LTD. :TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q3) ($MN)
      • TABLE 149     F. HOFFMANN-LA ROCHE LTD. :TOTAL REVENUE, BY DIAGNOSTIC SEGMENTS, (2017-2019) (Q3) ($MN)
      • TABLE 150     F. HOFFMANN-LA ROCHE LTD :TOTAL REVENUE, BY MOLECULAR DIAGNOSTIC IN REGIONS, (2017-2019) (Q3) ($MN)

      LIST OF FIGURES

      • FIGURE 1     MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: MOLECULAR DIAGNOSTICS GLOBAL MARKET
      • FIGURE 3     MOLECULAR DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     MOLECULAR DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     MOLECULAR DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     MOLECULAR DIAGNOSTICS GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MOLECULAR DIAGNOSTICS APPLICATIONS GLOBAL MARKET SEGMENTATION
      • FIGURE 8     MARKET DYNAMICS
      • FIGURE 9     MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS (2019)
      • FIGURE 10     INFECTIOUS DISEASES MARKET SHARE ANALYSIS, BY KEY PLAYERS (2019)
      • FIGURE 11     MOLECULAR DIAGNOTICS GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 12     MOLECULAR DIAGNOSTICS FUNDING SCENARIO, (2018-19)
      • FIGURE 13     MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY PRODUCT (2019 V’S 2026) (%)
      • FIGURE 14     MOLECULAR DIAGNOSTICS CONSUMABLES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 15     MOLECULAR DIAGNOSTICS SOFTWARE AND SERVICES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 16     MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE BY TECHNOLOGY AND CAGR (2019) (%)
      • FIGURE 17     PCR GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 18     MICROFLUIDS AND MICROARRAY GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 19     INAAT GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 20     IN-SITU HYBRIDIZATION GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 21     NGS GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 22     OTHERS GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 23     MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
      • FIGURE 24     INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 25     INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY ORGANSIM (2019 V’S 2026) (%)
      • FIGURE 26     BACTERIAL DISEASES GLOBAL MARKET REVENUE, BY TYPE OF INFECTION (2019 V’S 2026) ($MN)
      • FIGURE 27     BACTERIAL INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 28     SEXUALLY TRANSMITTED DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 29     HOSPITAL ACQUIRED INFECTIONS GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 30     TUBERCULOSIS GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 31     OTHER BACTERIAL DISEASE GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 32     VIRAL DISEASES GLOBAL MARKET REVENUE, BY TYPE OF INFECTION (2019 V’S 2026) ($MN)
      • FIGURE 33     VIRAL DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 34     HIV GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 35     INFLUENZA GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 36     HPV GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 37     OTHER VIRAL DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 38     OTHER INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 39     GENETIC TESTING GLOBAL MARKET SHARE, BY DISEASE (2019 V’S 2026) (%)
      • FIGURE 40     GENETIC TESTING GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 41     NIPT GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 42     ONCOLOGY TESTING GLOBAL MARKET SHARE, BY CANCER TYPE (2019) (%)
      • FIGURE 43     LUNG CANCER GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 44     ONCOLOGY GLOBAL MARKET SHARE, BY CANCER CARE (2019 V’S2026) (%)
      • FIGURE 45     TRANSPLANTION GLOBAL MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
      • FIGURE 46     BLOOD SCREENING GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 47     MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY END USERS (2019 V’S 2026) (%)
      • FIGURE 48     HOSPITALS GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 49     CLINICAL/CENTRALIZED LABORATORIES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 50     ACADEMICS AND RSEARCH GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
      • FIGURE 51     MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • FIGURE 52     MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION AND COUNTRY (2019) ($MN)
      • FIGURE 53     NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCTS (2019 V’S 2026) (%)
      • FIGURE 54     NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019) (%)
      • FIGURE 55     NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION (2019 V’S 2026) (%)
      • FIGURE 56     NORTH AMERICA INFECTIOUS DISEASES MARKET SHARE, BY ORGANISM (2019 V’S 2026) (%)
      • FIGURE 57     NORTH AMERICA BACTERIAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
      • FIGURE 58     NORTH AMERICA VIRAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
      • FIGURE 59     NORTH AMERICA GENETIC TESTING MARKET SHARE, BY DISEASE (2019 V’S 2026) (%)
      • FIGURE 60     NORTH AMERICA ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2019) (%)
      • FIGURE 61     NORTH AMERICA ONCOLOGY MARKET SHARE, BY CANCER CARE (2019 V’S 2026) (%)
      • FIGURE 62     NORTH AMERICA TRANSPLANTATION MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
      • FIGURE 63     NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER (2019 V’S 2026) (%)
      • FIGURE 64     NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 V’S 2026) (%)
      • FIGURE 65     U.S. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
      • FIGURE 66     U.S. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 V’S 2026) ($MN)
      • FIGURE 67     U.S. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
      • FIGURE 68     U.S. MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 V’S 2026) ($MN)
      • FIGURE 69     REST OF N.A. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
      • FIGURE 70     REST OF N.A. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 V’S 2026) ($MN)
      • FIGURE 71     REST OF N.A. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
      • FIGURE 72     REST OF N.A. MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER (2019 V’S 2026) ($MN)
      • FIGURE 73     EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCTS (2019 V’S 2026) (%)
      • FIGURE 74     EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019) (%)
      • FIGURE 75     EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION (2019 V’S 2026) (%)
      • FIGURE 76     EUROPE INFECTIOUS DISEASES MARKET SHARE, BY ORGANISM (2019 V’S 2026) (%)
      • FIGURE 77     EUROPE BACTERIAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
      • FIGURE 78     EUROPE VIRAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
      • FIGURE 79     EUROPE GENETIC TESTING MARKET SHARE, BY DISEASE (2019 VS 2026) (%)
      • FIGURE 80     EUROPE ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2019) (%)
      • FIGURE 81     EUROPE ONCOLOGY MARKET SHARE, BY CANCER CARE (2019 V’S 2026) (%)
      • FIGURE 82     EUROPE TRANSPLANTATION MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
      • FIGURE 83     EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER (2019 V’S 2026) (%)
      • FIGURE 84     EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 V’S 2026) (%)
      • FIGURE 85     FRANCE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
      • FIGURE 86     FRANCE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
      • FIGURE 87     FRANCE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
      • FIGURE 88     FRANCE MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USERS (2019 V’S 2026) ($MN)
      • FIGURE 89     GERMANY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
      • FIGURE 90     GERMANY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
      • FIGURE 91     GERMANY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 VS 2026) ($MN)
      • FIGURE 92     GERMANY MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 VS 2026) ($MN)
      • FIGURE 93     ITALY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
      • FIGURE 94     ITALY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
      • FIGURE 95     ITALY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
      • FIGURE 96     ITALY MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 V’S 2026) ($MN)
      • FIGURE 97     REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 98     REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
      • FIGURE 99     REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
      • FIGURE 100     REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2019 VS 2026) ($MN)
      • FIGURE 101     ASIA-PACIFIC DIAGNOSTICS MARKET SHARE, BY PRODUCTS (2019 V’S 2026) (%)
      • FIGURE 102     ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019) (%)
      • FIGURE 103     ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION (2019 V’S 2026) (%)
      • FIGURE 104     ASIA-PACIFIC INFECTIOUS DISEASES MARKET SHARE, BY ORGANISM (2019 V’S 2026) (%)
      • FIGURE 105     ASIA-PACIFIC BACTERIAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
      • FIGURE 106     ASIA-PACIFIC VIRAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 VS 2026) (%)
      • FIGURE 107     ASIA-PACIFIC GENETIC TESTING MARKET SHARE, BY DISEASE (2019 V’S 2026) (%)
      • FIGURE 108     ASIA-PACIFIC ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2019) (%)
      • FIGURE 109     ASIA-PACIFIC ONCOLOGY MARKET SHARE, BY CANCER CARE (2019 V’S 2026) (%)
      • FIGURE 110     ASIA-PACIFIC TRANSPLANTATION MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
      • FIGURE 111     ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER (2019 V’S 2026) (%)
      • FIGURE 112     ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 V’S 2026) (%)
      • FIGURE 113     CHINA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
      • FIGURE 114     CHINA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
      • FIGURE 115     CHINA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
      • FIGURE 116     CHINA MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 VS 2026) ($MN)
      • FIGURE 117     INDIA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
      • FIGURE 118     INDIA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
      • FIGURE 119     INDIA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
      • FIGURE 120     INDIA MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 VS 2026) ($MN)
      • FIGURE 121     JAPAN MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
      • FIGURE 122     JAPAN MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
      • FIGURE 123     JAPAN MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 VS 2026) ($MN)
      • FIGURE 124     JAPAN MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 VS 2026) ($MN)
      • FIGURE 125     REST OF ASIA-PACIFICMOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
      • FIGURE 126     REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
      • FIGURE 127     REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 VS 2026) ($MN)
      • FIGURE 128     REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER (2019 VS 2026) ($MN)
      • FIGURE 129     REST OF THE WORLD DIAGNOSTICS MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
      • FIGURE 130     REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019) (%)
      • FIGURE 131     REST OF THE WORLD DIAGNOSTICS MARKET SHARE, BY APPLICATION (2019 V’S 2026) (%)
      • FIGURE 132     REST OF THE WORLD INFECTIOUS DISEASES MARKET SHARE, BY ORGANISM (2019 VS 2026) (%)
      • FIGURE 133     REST OF THE WORLD BACTERIAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 VS 2026) (%)
      • FIGURE 134     REST OF THE WORLD VIRAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 VS 2026) (%)
      • FIGURE 135     REST OF THE WORLD GENETIC TESTING MARKET SHARE, BY DISEASE (2019 VS 2026) (%)
      • FIGURE 136     REST OF THE WORLD ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2019) (%)
      • FIGURE 137     REST OF THE WORLD ONCOLOGY MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
      • FIGURE 138     REST OF THE WORLD TRANSPLANTATION MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
      • FIGURE 139     REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER (2019 VS 2026) (%)
      • FIGURE 140     ROW MOLECULAR DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 V’S 2026) (%)
      • FIGURE 141     BRAZIL MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
      • FIGURE 142     BRAZIL MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
      • FIGURE 143     BRAZIL MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
      • FIGURE 144     BRAZIL MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER (2019 VS 2026) ($MN)
      • FIGURE 145     REST OF LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
      • FIGURE 146     REST OF LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
      • FIGURE 147     REST OF LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
      • FIGURE 148     REST OF LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2019 V’S 2026) ($MN)
      • FIGURE 149     MIDDLE EAST AND OTHERS MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
      • FIGURE 150     MIDDLE EAST AND OTHERS MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
      • FIGURE 151     MIDDLE EAST AND OTHERS MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
      • FIGURE 152     MIDDLE EAST AND OTHERS MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 V’S 2026) ($MN)
      • FIGURE 153     KEY GROWTH STRATEGIES, (2018-2019)
      • FIGURE 154     SWOT: ABBOTT LABORATORIES
      • FIGURE 155     SWOT: BECTON, DICKINSON AND COMPANY
      • FIGURE 156     SWOT: BIOMERIEUX
      • FIGURE 157     SWOT: DANAHER CORPORATION
      • FIGURE 158     SWOT: EXACT SCIENCES
      • FIGURE 159     SWOT: GRIFOLS
      • FIGURE 160     SWOT: HOLOGIC, INC
      • FIGURE 161     SWOT: MYRIAD GENETICS, INC
      • FIGURE 162     SWOT: QIAGEN N.V.
      • FIGURE 163     SWOT: ROCHE

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     23 ANDME
      • 2     3D MEDICINES
      • 3     ABBOTT LABORATORIES
      • 4     ABNOVA CORPORATION
      • 5     ACCUBIOTECH
      • 6     ACCURAGEN
      • 7     ADAPTHERAPY
      • 8     ADAPTIVE BIOTECHNOLOGIES
      • 9     ADMERA HEALTH
      • 10     ADVANCED CELL DIAGNOSTICS, INC.
      • 11     ADX HEALTHCARE
      • 12     AGENA BIOSCIENCE
      • 13     AGILENT TECHNOLOGIES INC.
      • 14     AKONNI BIOSYSTEMS, INC
      • 15     AMBRY GENETICS
      • 16     AMOY DIAGNOSTICS
      • 17     ANALYTIK JENA AG
      • 18     ANNOROAD GENE TECHNOLOGY
      • 19     ANPAC TECHNOLOGIES
      • 20     ASPIRA LABS
      • 21     AUTOGENOMICS
      • 22     BECTON, DICKINSON AND COMPANY
      • 23     BEIJING GENOMICS INSTITUTE (BGI)
      • 24     BERRY GENOMICS
      • 25     BINX HEALTH, INC
      • 26     BIO VIEW
      • 27     BIOARRAY SL
      • 28     BIOCARTIS
      • 29     BIOCEPT, INC.
      • 30     BIODESIX, INC
      • 31     BIOFLUIDICA
      • 32     BIOLYTICAL LABORATORIES INC.
      • 33     BIOMÉRIEUX
      • 34     BIONEER
      • 35     BIO-RAD LABORATORIES, INC.
      • 36     BIOSPHERIX, LTD.
      • 37     BIOTEK INSTRUMENTS INC.
      • 38     BIOTYPE
      • 39     BMG LABTECH INC.
      • 40     BRUKER CORPORATION
      • 41     CELLMAX LIFE
      • 42     CENTOGENE
      • 43     CERTEST BIOTEC
      • 44     CHEMBIO DIAGNOSTIC SYSTEMS, INC.
      • 45     CHRONIX BIOMEDICAL
      • 46     CIRCULOGENE
      • 47     CTK BIOTECH CO
      • 48     DANAHER CORPORATION
      • 49     DATAR GENETICS LIMITED
      • 50     DECIPHER BIOSCIENCES
      • 51     DELTAGENE
      • 52     DENKA SEIKEN
      • 53     DIASORIN
      • 54     DIAZYME LABORATORIES
      • 55     DISCOVERY LIFE SCIENCES
      • 56     DR LAL PATH LABS
      • 57     EDC BIOSYSTEMS INC.
      • 58     EIKEN CHEMICAL CO., LTD
      • 59     ENZO LIFE SCIENCES INC
      • 60     EPIGENOMICS AG
      • 61     EUROFINS
      • 62     EUROIMMUN
      • 63     EXACT SCIENCES CORPORATION
      • 64     EXOSOME DIAGNOSTICS, INC
      • 65     F. HOFFMANN-LA ROCHE AG
      • 66     FAST TRACK DIAGNOSTICS LTD.
      • 67     FIBROTX
      • 68     FIRALIS S.A.
      • 69     FLUIDIGM CORPORATION
      • 70     FOUNDATION MEDICINE
      • 71     FUJIREBIO
      • 72     FUSION GENOMICS
      • 73     GE HEALTHCARE
      • 74     GENECENTRIC THERAPEUTICS, INC
      • 75     GENEKAM BIOTECHNOLOGY AG
      • 76     GENEPOC INC
      • 77     GENEVIA TECHNOLOGIES
      • 78     GENLANTIS INC.
      • 79     GENOMEME
      • 80     GREAT BASIN SCIENTIFIC, INC.
      • 81     GREINER BIO-ONE AG
      • 82     GRIFOLS, S.A.
      • 83     GUARDANT HEALTH
      • 84     GYROS AB
      • 85     HAMILTON COMPANY
      • 86     HIBERGENE DIAGNOSTICS
      • 87     HOLOGIC, INC
      • 88     HUMASIS
      • 89     HUMMINGBIRD DIAGNOSTICS GMBH
      • 90     ICUBATE
      • 91     ILLUMINA
      • 92     IMMUCOR, INC.
      • 93     INFLAMMATIX, INC.
      • 94     INIVATA
      • 95     INVITAE CORPORATION
      • 96     IVYGENE LABS
      • 97     JENA BIOSCIENCE
      • 98     KAILOS GENETICS INC
      • 99     KERN AND SOHN GMBH
      • 100     LABCYTE INC.
      • 101     LABORATORY CORP. OF AMERICA HOLDINGS
      • 102     LCM GENECT SRL
      • 103     LIFERIVER BIOTECH CORP.
      • 104     LIQUID BIOTECH USA
      • 105     LONZA GROUP AG
      • 106     LUCENCE DIAGNOSTICS
      • 107     LUCIGEN CORPORATION
      • 108     LUMINEX CORPORATION
      • 109     LUNGLIFEAI (CYNVENIO BIOSYSTEMS )
      • 110     MAPMYGENOME
      • 111     MDXHEALTH
      • 112     MEDGENOME
      • 113     MENARINI SILICON BIOSYSTEMS
      • 114     MERCK KGAA
      • 115     MERIDIAN BIOSCIENCE
      • 116     MICROGENOMICS SRL
      • 117     MILTENYI BIOTEC
      • 118     MIRXES PTE LTD
      • 119     MOLBIO DIAGNOSTICS PVT. LTD.
      • 120     MYRIAD GENETICS
      • 121     NANOSTICS
      • 122     NANOSTRING TECHNOLOGIES
      • 123     NEOGENOMICS LABORATORIES, INC.
      • 124     NEUMODX
      • 125     NOWDIAGNOSTICS
      • 126     NUCLEIX
      • 127     OMEGA DIAGNOSTICS
      • 128     ONCODIAG
      • 129     ONCODNA
      • 130     OPKO HEALTH, INC.
      • 131     OPTIGENE LIMITED
      • 132     ORASURE TECHNOLOGIES
      • 133     OXFORD GENE TECHNOLOGY
      • 134     PACIFIC BIOSCIENCES OF CALIFORNIA
      • 135     PANAGENE
      • 136     PATHWAY GENOMICS
      • 137     PERKIN ELMER, INC.
      • 138     PERSONAL GENOME DIAGNOSTICS
      • 139     PERTH OBSTETRICS & GYNECOLOGY ULTRASOUND
      • 140     PRECIPIODX
      • 141     PREDICINE, INC
      • 142     PRIMERADX
      • 143     PRIMERDESIGN LTD.
      • 144     PROGENITY
      • 145     PROMEGA CORPORATION
      • 146     PTS DIAGNOSTICS
      • 147     QIAGEN N.V.
      • 148     QUIDEL CORPORATION
      • 149     RENISHAW DIAGNOSTICS LTD.,
      • 150     RESOLUTION BIOSCIENCES
      • 151     SAGA DIAGNOSTICS
      • 152     SANOFI
      • 153     SIEMENS
      • 154     SPECTRAL MEDICAL INC
      • 155     SPHINGOTEC GMBH
      • 156     SPT LABTECH
      • 157     SQI DIAGNOSTICS
      • 158     STAGEZERO LIFE SCIENCES
      • 159     STRAND LIFESCIENCES
      • 160     SYNLAB INTERNATIONAL
      • 161     SYSMEX INOSTICS
      • 162     TAI DIAGNOSTICS
      • 163     TECAN GROUP LTD
      • 164     THE ELITECH GROUP
      • 165     THERADIAG
      • 166     THERMO FISHER SCIENTIFIC INC.
      • 167     TRANSPLANT GENOMICS, INC.
      • 168     TRINITY BIOTECH
      • 169     TROVAGENE, INC
      • 170     TULIP GROUP/QUALPRO
      • 171     VELA DIAGNOSTICS
      • 172     VERAGEN
      • 173     VEREDUS LABORATORIES
      • 174     VICTORIAN CLINICAL GENETICS SERVICES
      • 175     WELLSBIO
      • 176     YOURGENE BIOSCIENCES CO., LTD., (PREMAITHA HEALTH)